Jinhan Kim

Jinhan Kim is the Co-Founder, Chairman, and CEO of Standigm, and is an expert in developing AI platforms to identify new drug candidates and has led the company since its inception in May 2015.

Before founding Standigm, Kim worked as a Senior Research Scientist at the Samsung Advanced Institute of Technology, where he developed an AI algorithm for DNA damage and recovery mechanisms. He previously worked as a software developer for NCSOFT and for Namo Interactive. He also served as the Director of Drug Informatics at the Korean Society of Medical Informatics from January 2017-January 2020.

Jinhan Kim earned his Ph.D. in Artificial Intelligence at the University of Edinburgh, his M.S. in Artificial Intelligence at Seoul National University, and his bachelor’s degree in Applied Biology and Chemistry from Seoul National University. Kim speaks Korean and English.

Standigm

Standigm is a workflow AI-driven drug discovery company, founded by Jinhan Kim. Standigm has proprietary AI platforms encompassing novel target identification to lead generation to generate commercially valuable drug pipelines. Founded in 2015, the company has established an early-stage drug discovery workflow AI to generate First-in-Class lead compounds within seven months.

Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow through DarkMolFactory™, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASK™ for target discovery, Standigm BEST™ for lead design, and Standigm Insight™ for drug repurposing.

Jinhan Kim is also featured on our premiere Features Page.